PTSD Trial, Recruiting NCT06854328 Sponsor: GrayMatters Health Ltd. Condition: PTSD
Back to Ptsd

PTSD Trial, Recruiting

NCT06854328
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 12 to 21 years old
  • People of any gender
  • People who have been diagnosed with PTSD (Post-Traumatic Stress Disorder) according to the standard medical guidelines (DSM-5)
  • People for whom at least 1 year has passed since the traumatic event that led to their PTSD diagnosis
  • For those under 18: people who are willing and able to give their own agreement to take part, with a parent or legal guardian also willing to give formal consent on their behalf
  • For those aged 18 and over: people who are willing and able to give their own formal consent to take part
  • People who can speak, read, and write in English
  • People who have normal vision and hearing, or vision and hearing that is fully corrected (for example, with glasses or hearing aids)

Who may not be able to join:

  • People who have already completed one or more full courses of a trauma-focused therapy in the past (such as EMDR or Prolonged Exposure Therapy) — the trial investigator will make this judgement on a case-by-case basis
  • People who have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder
  • People whose main focus of mental health treatment in the past 6 months has been a mood or anxiety disorder (such as depression or generalised anxiety), as determined by the site investigator
  • People diagnosed with autism spectrum disorder that requires substantial support, or with at least mild intellectual disability — the investigator will assess this on a case-by-case basis
  • People diagnosed with a moderate or severe substance use disorder (such as serious problems with alcohol or drugs) within the last 3 months before the screening visit
  • People currently experiencing moderate or severe ADHD symptoms, as assessed at the screening visit
  • People who have changed or started any psychiatric medication within the past 4 weeks, or who plan to change their medication or psychological therapy during the study
  • People who have made a suicide attempt or engaged in suicidal behaviour in the past year before or during the screening period
  • People who have started a new course of cognitive-behavioural therapy or a recognised PTSD treatment (such as CPT, Prolonged Exposure, or EMDR) within the past 3 months — note that continuing an already-established, ongoing supportive therapy is permitted
  • People with a history of brain surgery, serious brain injury, epilepsy, stroke-related brain injury, brain infection, or other major neurological conditions, including a traumatic brain injury that caused loss of consciousness for more than 24 hours or memory loss lasting more than 7 days
  • People with an unstable medical condition, as determined by the trial investigator
  • People who are currently enrolled in another clinical trial, have been in one within the past 2 months, or plan to join another trial during this study
  • People who are pregnant, breastfeeding, or planning to become pregnant during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ADAR SHANI, GrayMatters Health

Phone: +972-524897823

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
GrayMatters Health Ltd.
Registry
ClinicalTrials.gov
Start date
11 June 2025
Est. completion
1 August 2026

Where this trial is recruiting

🇮🇱 Israel 🇺🇸 United States

Primary endpoints

Safety reporting

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov